UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042106
Receipt number R000048052
Scientific Title The impact of COVID19 pandemic-related activity restriction on the outcomes of chronic obstructive lung disease
Date of disclosure of the study information 2020/10/15
Last modified on 2023/04/17 09:34:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The impact of COVID19 pandemic-related activity restriction on the outcomes of chronic obstructive lung disease

Acronym

ICARD study

Scientific Title

The impact of COVID19 pandemic-related activity restriction on the outcomes of chronic obstructive lung disease

Scientific Title:Acronym

ICARD study

Region

Japan


Condition

Condition

chronic obstructive lung disease(COPD)

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine the impact of COVID19 pandemic-related activity restriction on the outcomes of chronic obstructive lung disease

Basic objectives2

Others

Basic objectives -Others

This study is aimed to investigate the actual situation of COVID19 pandemic-related activity restriction in COPD patients and to evaluate the impact of activity restriction on COPD-related outcomes.

Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Physical activity evaluated by IPAQ during COVID19 pandemic period

Key secondary outcomes

1. Sedentary time during COVID19 pandemic period
2. Prevalence of COVID19 in this study population
3. The numbers of COPD-related acute exacerbation (AE) after COVID19 pandemic
4. The chance of spirometric valuables after COVID19 pandemic
5. Estimation of anxiety and depression evaluated by HADS on enroll
6. Identification of factors related to COPD-AE


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

COPD: Patients who meet three criteria:
(1-1) cases diagnosed as COPD on registration
(2) above 40 years-old
(3) written informed consent
Non-COPD: Patients who meet three criteria:
(1-2) never-smokers with FEV1/FVC >70%
(2) above 40 years-old
(3) written informed consent

Key exclusion criteria

(1) cases who disagree with evaluation of COPD status
(2) cases who investigators could not evaluate the incidence of COPD-related AE by medical record
(3) cases carrying malignant tumors
(4) cases with asthma

Target sample size

150


Research contact person

Name of lead principal investigator

1st name Naozumi
Middle name
Last name Hashimoto

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Respiratory Medicine

Zip code

4668550

Address

65 Tsurumai, Showa-Ku, Nagoya, Aichi, Japan

TEL

0527442167

Email

hashinao@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name Akira
Middle name
Last name Ando

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Respiratory Medicine

Zip code

4668550

Address

65 Tsurumai, Showa-Ku, Nagoya, Aichi, Japan

TEL

0527442167

Homepage URL


Email

ICARD.kokyuki@outlook.jp


Sponsor or person

Institute

Nagoya University

Institute

Department

Personal name



Funding Source

Organization

Department of Respiratory Medicine,
Nagoya University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

the Nagoya University Ethics Committee

Address

65 Tsurumai-cho, Showa-ku, Nagoya, Japan

Tel

052-741-2111

Email

ethics@med.nagoya-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 10 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

122

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 08 Month 09 Day

Date of IRB

2020 Year 08 Month 27 Day

Anticipated trial start date

2020 Year 09 Month 01 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry

2023 Year 03 Month 31 Day

Date trial data considered complete

2023 Year 03 Month 31 Day

Date analysis concluded

2024 Year 03 Month 31 Day


Other

Other related information

Observationa Study ongoing


Management information

Registered date

2020 Year 10 Month 14 Day

Last modified on

2023 Year 04 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048052


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name